![]() ![]() ![]() Presentation on Public & Patient Involvement/Engagement (PPIE), Laura Chapman, University Hospitals Birmingham & Mandy Lomax, Patient Representative - Download Presentation on PPIE.pdf. Presentation on vascular liver disease, David Patch, Royal Free Hospital, London - Download BASL SIG2 2019 Vascular Liver Disease Patch.pdf. Presentation on vascular liver disease: MPN SVT, Frederick Chen, Barts Health NHS Trust - Download BASL talk 1.5.19 Vascular Liver Disease Chen.pdf. Presentation on ASEPTIC trial, Alastair O'Brien, University College London - Download SIG_BASL_BSG_ASEPTIC.pdf. Presentation on BOPP trial, Vish Patel & Mark McPhail, Kings College Hospital London - Download BOPPP Overview_Portal HTN SiG Birmingham_.pdf. Presentation on CALIBRE trial, Khaled Ahmed, University of Birmingham - Download Khaled Ahmed (Abdul) BASL SIG V2.pdf. Presentation on CALIBRE trial, Dhiraj Tripathi, University Hospitals Birmingham - Download CALIBRE_Presentation_BASL_PortalHypertensionSIG.pdf. Meeting report - Download BASL Portal Hypertension Special Interest Group Inaugural Meeting Report._.pdf. Steering Committee meeting - Download BASL Portal Hypertension SIG Steering Committee Meeting Minutes_17.6.20.pdf ResourcesĪnnual report 2018-19 - Download Annual report_2018-19_PH SIG.pdf. Professor Adrian Stanley, Glasgow Royal Infirmaryĭr Emmanouil Tsochatzis, University College London Steering Committee Minutes Professor Peter Hayes, University of Edinburghĭr Joanna Leithead, Addenbrookes Hospital, Cambridgeĭr Raj Mookerjee, University College Londonĭr David Patch, University College London Professor Jonathan Fallowfield, University of Edinburgh Steering Committeeĭr Dhiraj Tripathi (Chair), University Hospitals Birminghamĭr Abhishek Chauhan, University Hospitals Birmingham, Trainee representative If anyone wishes to join this group please contact the BASL Secretariat at. The SIG Lead is Dr Dhiraj Tripathi of University Hospitals Birmingham. There is also much debate on the best management of patients with regard to medical and radiological therapies. Translational research has been boosted by studies on non-invasive assessment of Portal Hypertension, and exciting new drugs. Portal Hypertension is a very active research area, with recent NIHR HTA funding of two randomised controlled trials which have the potential to become the largest ever clinical trials in cirrhosis. The SIG is linked to Cirrhosis and its Complications CRN topic area. The Portal Hypertension Special Interest Group (SIG) was established to facilitate collaborations in clinical and translational research, and to provide a platform to nurture discussion in best management of patients in this complex and rapidly evolving area. Portal Hypertension Special Interest Group ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |